financetom
Business
financetom
/
Business
/
Market Chatter: Critical Metals Not Considered for Equity Stake Deal, White House Official Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Critical Metals Not Considered for Equity Stake Deal, White House Official Says
Oct 6, 2025 11:03 AM

01:30 PM EDT, 10/06/2025 (MT Newswires) -- Critical Metals (CRML) is currently not being considered for an equity stake deal by the Trump Administration, Bloomberg reported Monday, citing a White House official.

The US government is in touch with the private sector and has received multiple deal proposals related to equity stakes, but is not actively mulling an agreement with the rare earths company that has an interest in Greenland's biggest rare earths project, the official told the media outlet.

Critical Metals and the White House did not immediately respond to requests for comment from MT Newswires.

Shares of the company gained more than 57% in recent trading Monday.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 12.55, Change: +4.57, Percent Change: +57.32

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree
Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree
Jan 27, 2025
09:35 AM EST, 01/27/2025 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) said Monday the US Food and Drug Administration has cleared a label update for qelbree, a treatment for attention-deficit/hyperactivity disorder, or ADHD. The updated label describes the drug's partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter, which highlights the treatment's multimodal pharmacodynamic...
Thyssenkrupp CEO predicts decisive year in company's transformation
Thyssenkrupp CEO predicts decisive year in company's transformation
Jan 27, 2025
DUESSELDORF (Reuters) - The CEO of German industrial group Thyssenkrupp said on Monday that 2025 would be a decisive year for the group's ongoing transformation. The current business year will be a year of decision-making when it comes to our portfolio, CEO Miguel Lopez said in a transcript of his speech to shareholders, to be delivered at the company's annual...
Sage rejects Biogen's $469 million takeover offer
Sage rejects Biogen's $469 million takeover offer
Jan 27, 2025
Jan 27 (Reuters) - Sage Therapeutics ( SAGE ) said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.22 apiece, significantly undervalues Sage and believes it is not in the best interest of shareholders....
3M Insider Sold Shares Worth $346,241, According to a Recent SEC Filing
3M Insider Sold Shares Worth $346,241, According to a Recent SEC Filing
Jan 27, 2025
09:33 AM EST, 01/27/2025 (MT Newswires) -- Theresa E Reinseth, Sr Vice President & CAO, on January 24, 2025, sold 2,309 shares in 3M ( MMM ) for $346,241. Following the Form 4 filing with the SEC, Reinseth has control over a total of 4,975 shares of the company, with 4,417 shares held directly and 558 controlled indirectly. SEC Filing:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved